Drug intelligence / Profile preview

Lactococcus lactis LB1022

Development stage: Preclinical
Lead developer: LuxBiome
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

*Lactococcus lactis* LB1022 is a specific probiotic bacterial strain investigated for its role in preventing the "atopic march," the clinical progression from atopic dermatitis (AD) to allergic airway diseases such as asthma. Often studied in combination with fructo-oligosaccharides (FOS) as a synbiotic, LB1022 modulates the gut microbiota to favor the growth of short-chain fatty acid (SCFA)-producing taxa like *Lactobacillus* and *Bifidobacterium*. This shift increases fecal SCFA concentrations, which in turn regulates systemic and mucosal immunity by suppressing Th2-skewed cytokine responses and reducing serum IgE and Th2-associated IgG1 levels. The strain's activity is characterized by its ability to coordinate the microbiota-gut-skin-lung axis to mitigate both epidermal and respiratory allergic inflammation.

Other names: L. lactis LB1022

Beyond the preview

Go deeper on Lactococcus lactis LB1022.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lactococcus lactis LB1022.

Explore the full profile